益气理肺方辅助治疗支气管哮喘临床研究

Clinical Study of Yiqi Lifei Prescription for Adjuvant Treatment of Bronchial Asthma

目的:研究益气理肺方辅助治疗支气管哮喘的临床疗效及对炎症因子、肺功能的影响。方法:选取湖州市中心医院呼吸科2020年1月—2022年12月收治的支气管哮喘患者100例,采用随机数字表法将患者分为观察组和对照组各50例。2组均给予支气管哮喘常规治疗,对照组在常规治疗的基础上加用孟鲁司特钠治疗,观察组在常规治疗的基础上予孟鲁司特钠联合益气理肺方治疗,2组持续治疗1个月,观察2组临床疗效,比较治疗前后2组肺功能、炎症因子水平、T淋巴细胞免疫功能以及中医证候积分。结果:治疗后,临床疗效总有效率观察组94.00%,对照组68.00%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组第1秒用力呼气量(FEV1)、用力肺活量(FVC)及呼气流量峰值(PEF)均较治疗前升高,且观察组高于对照组,差异均有统计学意义(P<0.05)。治疗后,2组白细胞介素-6 (IL-6)、白细胞介素-8 (IL-8)、肿瘤坏死因子-α (TNF-α)水平均较治疗前下降,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组T淋巴细胞CD3+、CD4+水平均上升,且观察组高于对照组,差异均有统计学意义(P<0.05);2组T淋巴细胞CD8+水平较治疗前下降,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组中医证候积分均较治疗前下降,且观察组低于对照组,差异均有统计学意义(P<0.05)。结论:益气理肺方辅助治疗支气管哮喘能有效降低炎症因子水平,提高细胞免疫力,增强肺功能。

Objective:To study the clinical efficacy of Yiqi Lifei Prescription in the adjuvant treatment of bronchial asthma and its effect on inflammatory factors and lung function.Methods:A total of 100 cases of patients with bronchial asthma admitted to the Respiratory Department of Huzhou Central Hospital from January 2020 to December 2022 were selected and divided into the observation group and the control group according to the random number table method,with 50 cases in each group.Both groups were given routine treatment for bronchial asthma;the control group was additionally treated with Montelukast Sodium on the basis of conventional treatment,and the observation group was additionally treated with Montelukast Sodium combined with Yiqi Lifei Prescription on the basis of conventional treatment.Both groups were treated for one month.Observed the clinical effects in the two groups,and compared the lung function and levels of inflammatory factors,T lymphocyte immune function and traditional Chinese medicine syndrome scores between the two groups before and after treatment.Results:After treatment,the total effective rate of clinical effect was 94.00%in the observation group and 68.00%in the control group,the difference between the two groups being significant(P<0.05).After treatment,forced expiratory volume in the first second(FEV1),forced vital capacity(FVC)and peak expiratory flow(PEF)in the two groups were increased when compared with those before treatment,and the above indexes in the observation group were higher than those in the control group,differences being significant(P<0.05).After treatment,the levels of interleukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in the two groups were decreased when compared with those before treatment,and the levels in the observation group were lower than those in the control group,differences being significant(P<0.05).After treatment,the levels of T lymphocyte CD3+and CD4+were elevated in the two groups when compared with those before treatment,and the levels in the observation group were higher than those in the control group,differences being significant(P<0.05);T lymphocyte CD8+levels were reduced in the two groups when compared with those before treatment,and the level in the observation group was lower than that in the control group,with significant differences(P<0.05).After treatment,traditional Chinese medicine syndrome scores in the two groups were decreased,and the score in the observation group was lower than that in the control group,differences being significant(P<0.05).Conclusion:Yiqi Lifei Prescription in the adjuvant treatment of bronchial asthma can effectively reduce the levels of inflammatory factors,improve cellular immune function and enhance lung function.